Deciphering the cell surface glyco-code: a promising perspective on unveiling the vulnerability of cancer stem cells

References

1. 1.↵
   2. Ren X,
   3. Lin S,
   4. Guan F,
   5. Kang H.

   Glycosylation targeting: a paradigm shift in cancer immunotherapy. Int J Biol Sci. 2024; 20: 2607.

   OpenUrlPubMed
2. 2.↵
   2. RodrÍguez E,
   3. Schetters STT,
   4. van Kooyk Y.

   The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018; 18: 204–11.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Matsumoto Y,
   3. Ju T.

   Aberrant glycosylation as immune therapeutic targets for solid tumors. Cancers. 2023; 15: 3536.

   OpenUrlPubMed
4. 4.↵
   2. Smith BA,
   3. Bertozzi CR.

   The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nat Rev Drug Discov. 2021; 20: 217–43.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Loong JH,
   3. Wong TL,
   4. Tong M,
   5. Sharma R,
   6. Zhou L,
   7. Ng KY, et al.

   Glucose deprivation-induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma. J Clin Invest. 2021; 131: e143377.
6. 6.↵
   2. Walker MR,
   3. Goel HL,
   4. Mukhopadhyay D,
   5. Chhoy P,
   6. Karner ER,
   7. Clark JL, et al.

   O-linked α2,3 sialylation defines stem cell populations in breast cancer. Sci Adv. 2022; 8: eabj9513.
7. 7.↵
   2. Wei Y,
   3. Chen Q,
   4. Huang S,
   5. Liu Y,
   6. Li Y,
   7. Xing Y, et al.

   The interaction between DNMT1 and high-mannose CD133 maintains the slow-cycling state and tumorigenic potential of glioma stem cell. Adv Sci (Weinh). 2022; 9: e2202216.
8. 8.↵
   2. Liang YJ,
   3. Ding Y,
   4. Levery SB,
   5. Lobaton M,
   6. Handa K,
   7. Hakomori SI.

   Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013; 110: 4968–73.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   2. Zhang D,
   3. Yang L,
   4. Liu X,
   5. Gao J,
   6. Liu T,
   7. Yan Q, et al.

   Hypoxia modulates stem cell properties and induces EMT through N-glycosylation of EpCAM in breast cancer cells. J Cell Physiol. 2020; 235: 3626–33.

   OpenUrlPubMed
10. 10.↵
    2. Liu K,
    3. Jiang L,
    4. Shi Y,
    5. Liu B,
    6. He Y,
    7. Shen Q, et al.

    Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation. Cell Death Differ. 2022; 29: 1834–49.

    OpenUrlPubMed
11. 11.↵
    2. Schultz MJ,
    3. Holdbrooks AT,
    4. Chakraborty A,
    5. Grizzle WE,
    6. Landen CN,
    7. Buchsbaum DJ, et al.

    The Tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016; 76: 3978–88.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Oo HZ,
    3. Seiler R,
    4. Black PC,
    5. Daugaard M.

    Post-translational modifications in bladder cancer: expanding the tumor target repertoire. Urol Oncol. 2020; 38: 858–66.

    OpenUrlPubMed
13. 13.↵
    2. Martínez-Bailén M,
    3. Rojo J,
    4. Ramos-Soriano J.

    Multivalent glycosystems for human lectins. Chem Soc Rev. 2023; 52: 536–72.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Wei Y,
    3. Shi D,
    4. Liang Z,
    5. Liu Y,
    6. Li Y,
    7. Xing Y, et al.

    IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol. 2019; 71: 1206–15.

    OpenUrlPubMed
15. 15.↵
    2. Liang Z,
    3. Wu B,
    4. Ji Z,
    5. Liu W,
    6. Shi D,
    7. Chen X, et al.

    The binding of LDN193189 to CD133 C-terminus suppresses the tumorigenesis and immune escape of liver tumor-initiating cells. Cancer Lett. 2021; 513: 90–100.

    OpenUrlPubMed
16. 16.↵
    2. Kikushige Y,
    3. Miyamoto T,
    4. Yuda J,
    5. Jabbarzadeh-Tabrizi S,
    6. Shima T,
    7. Takayanagi S, et al.

    A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015; 17: 341–52.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Sanji AS,
    3. Manasa J,
    4. Gurav MJ,
    5. Batra SK,
    6. Chachadi VB.

    Cancer snap-shots: biochemistry and glycopathology of O-glycans: a review. Int J Biol Macromol. 2024; 260: 129318.
18. 18.↵
    2. Wei Y,
    3. Chen Q,
    4. Chen J,
    5. Zhou C,
    6. Geng S,
    7. Shi D, et al.

    Loss of α-1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction. Cell Rep. 2023; 42: 113588.
19. 19.↵
    2. Li C,
    3. Du Y,
    4. Yang Z,
    5. He L,
    6. Wang Y,
    7. Hao L, et al.

    GALNT1-mediated glycosylation and activation of sonic hedgehog signaling maintains the self-renewal and tumor-initiating capacity of bladder cancer stem cells. Cancer Res. 2016; 76: 1273–83.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Barkal AA,
    3. Brewer RE,
    4. Markovic M,
    5. Kowarsky M,
    6. Barkal SA,
    7. Zaro BW, et al.

    CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572: 392–6.

    OpenUrlCrossRefPubMed